Completed PHASE1 INTERVENTIONAL 5-arm NCT01927159

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults

Sponsor: Access to Advanced Health Institute (AAHI)

Conditions Pulmonary Tuberculosis

Interventions ID93 + GLA-SE Placebo

Updated 8 times since 2017 Last updated: Jan 30, 2018 Started: Sep 30, 2013 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pulmonary Tuberculosis, this trial is completed. The trial is conducted by Access to Advanced Health Institute (AAHI) and has accumulated 8 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Oct 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Access to Advanced Health Institute (AAHI)
Aeras
South African Tuberculosis Vaccine Initiative

Data source: Access to Advanced Health Institute (AAHI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Worcester, South Africa